JP2013540807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540807A5 JP2013540807A5 JP2013535564A JP2013535564A JP2013540807A5 JP 2013540807 A5 JP2013540807 A5 JP 2013540807A5 JP 2013535564 A JP2013535564 A JP 2013535564A JP 2013535564 A JP2013535564 A JP 2013535564A JP 2013540807 A5 JP2013540807 A5 JP 2013540807A5
- Authority
- JP
- Japan
- Prior art keywords
- naltrexone
- pharmaceutically acceptable
- formulation
- layer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 12
- 229960003086 naltrexone Drugs 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 238000009472 formulation Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 8
- 206010038678 Respiratory depression Diseases 0.000 claims 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 8
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 229960005181 morphine Drugs 0.000 claims 4
- 229960002085 oxycodone Drugs 0.000 claims 4
- 239000008188 pellet Substances 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 238000013270 controlled release Methods 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 239000004084 narcotic analgesic agent Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229940124636 opioid drug Drugs 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40675210P | 2010-10-26 | 2010-10-26 | |
| US61/406,752 | 2010-10-26 | ||
| PCT/IB2011/054767 WO2012056402A2 (en) | 2010-10-26 | 2011-10-25 | Formulations and methods for attenuating respiratory depression induced by opioid overdose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013540807A JP2013540807A (ja) | 2013-11-07 |
| JP2013540807A5 true JP2013540807A5 (enExample) | 2014-10-09 |
Family
ID=45470606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535564A Pending JP2013540807A (ja) | 2010-10-26 | 2011-10-25 | オピオイド過量投与によって誘発される呼吸抑制を減弱する製剤および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20140030343A1 (enExample) |
| EP (1) | EP2632442A2 (enExample) |
| JP (1) | JP2013540807A (enExample) |
| KR (3) | KR20170102571A (enExample) |
| CN (1) | CN103189055A (enExample) |
| AU (1) | AU2011322147A1 (enExample) |
| BR (1) | BR112013009267A2 (enExample) |
| CA (1) | CA2814230A1 (enExample) |
| IL (1) | IL225966A0 (enExample) |
| MX (1) | MX2013003832A (enExample) |
| RU (1) | RU2541159C2 (enExample) |
| SG (1) | SG189234A1 (enExample) |
| WO (1) | WO2012056402A2 (enExample) |
| ZA (1) | ZA201302363B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2539904T3 (es) | 2000-02-08 | 2015-07-07 | Euro-Celtique S.A. | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas |
| US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| KR20170102571A (ko) * | 2010-10-26 | 2017-09-11 | 알파마 파머슈티컬스 엘엘씨 | 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법 |
| MX2013008225A (es) * | 2011-02-02 | 2013-08-12 | Alpharma Pharmaceuticals Llc | Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado. |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
| RU2020128323A (ru) | 2015-12-22 | 2020-10-06 | Зодженикс Интернэшнл Лимитед | Фенфлураминовые композиции и способы их получения |
| EP3393470B1 (en) | 2015-12-22 | 2021-01-20 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| WO2017180659A1 (en) * | 2016-04-11 | 2017-10-19 | Arizona Board Of Regents On Behalf Of University Of Arizona | Opioid receptor modulators |
| US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
| KR20250040753A (ko) | 2016-08-24 | 2025-03-24 | 조게닉스 인터내셔널 리미티드 | 5-ht2b 작용물질의 형성을 억제하기 위한 제제 및 그것의 사용 방법 |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| EP3727384A4 (en) | 2017-12-20 | 2021-11-03 | Purdue Pharma L.P. | ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES |
| EP3790537A1 (en) | 2018-05-11 | 2021-03-17 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| WO2019241005A1 (en) * | 2018-06-14 | 2019-12-19 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| EP3883555A1 (en) | 2018-11-19 | 2021-09-29 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| US20240100120A1 (en) * | 2019-10-11 | 2024-03-28 | Board Of Regents, The University Of Taxas System | Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| AU2022380482A1 (en) | 2021-11-02 | 2024-05-16 | Enalare Therapeutics Inc. | Methods of treating respiratory depression modulated by a non-opioid agent |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL367427A1 (en) * | 2001-08-06 | 2005-02-21 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
| AU2004296821B2 (en) * | 2003-12-05 | 2011-05-12 | Carefusion 303, Inc. | Patient-controlled analgesia with patient monitoring system |
| EP1931593A4 (en) | 2005-10-07 | 2009-04-22 | Univ Florida | MULTIPLE COMPONENT NANOPARTICLES FOR MULTIPLEX SIGNALING AND OPTICAL CODING |
| JP2010506833A (ja) * | 2006-10-11 | 2010-03-04 | アルファーマ，インコーポレイテッド | 医薬組成物 |
| EP2197427A2 (en) * | 2007-09-04 | 2010-06-23 | Alpharma, Inc. | A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer |
| EP2224805A4 (en) * | 2007-12-17 | 2013-10-16 | Alpharma Pharmaceuticals Llc | PHARMACEUTICAL COMPOSITION |
| US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| CN102231991A (zh) | 2008-07-31 | 2011-11-02 | 生物工程大学精神物质实验室 | 应用于生物分析的活性粒子及其制备方法 |
| IT1391530B1 (it) | 2008-07-31 | 2012-01-11 | Cyanagen S R L | Particelle attive per applicazioni bio-analitiche e metodi per la loro preparazione |
| KR20170102571A (ko) * | 2010-10-26 | 2017-09-11 | 알파마 파머슈티컬스 엘엘씨 | 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법 |
-
2011
- 2011-10-25 KR KR1020177024247A patent/KR20170102571A/ko not_active Ceased
- 2011-10-25 JP JP2013535564A patent/JP2013540807A/ja active Pending
- 2011-10-25 US US13/881,758 patent/US20140030343A1/en not_active Abandoned
- 2011-10-25 KR KR1020167003000A patent/KR20160017668A/ko not_active Ceased
- 2011-10-25 EP EP11807744.5A patent/EP2632442A2/en not_active Withdrawn
- 2011-10-25 RU RU2013117274/15A patent/RU2541159C2/ru not_active IP Right Cessation
- 2011-10-25 BR BR112013009267A patent/BR112013009267A2/pt not_active IP Right Cessation
- 2011-10-25 CN CN201180051633XA patent/CN103189055A/zh active Pending
- 2011-10-25 SG SG2013024583A patent/SG189234A1/en unknown
- 2011-10-25 MX MX2013003832A patent/MX2013003832A/es not_active Application Discontinuation
- 2011-10-25 AU AU2011322147A patent/AU2011322147A1/en not_active Abandoned
- 2011-10-25 CA CA2814230A patent/CA2814230A1/en not_active Abandoned
- 2011-10-25 WO PCT/IB2011/054767 patent/WO2012056402A2/en not_active Ceased
- 2011-10-25 KR KR1020137010558A patent/KR20130097211A/ko not_active Ceased
-
2013
- 2013-04-02 ZA ZA2013/02363A patent/ZA201302363B/en unknown
- 2013-04-25 IL IL225966A patent/IL225966A0/en unknown
-
2015
- 2015-10-26 US US14/922,474 patent/US20160045449A1/en not_active Abandoned
-
2017
- 2017-04-27 US US15/498,617 patent/US20170367987A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013540807A5 (enExample) | ||
| RU2013117274A (ru) | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов | |
| JP2009143964A5 (enExample) | ||
| JP2013151541A5 (enExample) | ||
| RU2013136350A (ru) | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист | |
| JP2011137020A5 (enExample) | ||
| WO2007013975A3 (en) | Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications | |
| NZ629468A (en) | Tamper resistant immediate release formulations | |
| JP2017537168A5 (enExample) | ||
| JP2014504630A5 (enExample) | ||
| JP2009525343A5 (enExample) | ||
| JP2015044834A5 (enExample) | ||
| JP2017128614A5 (enExample) | ||
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| AU2018370000B2 (en) | Treatment of opioid use disorder, opioid withdrawal symptoms, and chronic pain | |
| WO2004091512A3 (en) | Abuse-resistant oral dosage forms and method of use thereof | |
| JP2016535773A5 (enExample) | ||
| JP2008511604A5 (enExample) | ||
| JP2015523407A5 (enExample) | ||
| JP2014528431A5 (enExample) | ||
| WO2013092589A1 (en) | Multiple unit pellet tablet formulation comprising an opioid | |
| JP2011519930A5 (enExample) | ||
| JP2013537915A5 (enExample) | ||
| WO2011140446A3 (en) | Pharmaceutical formulations | |
| JP2009517466A5 (enExample) |